Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 27, 2005. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general corporate financial performance.
Material Changes
The filing details a re-valuation of the cash element of a notional investment held within the US Retirement Savings Plan ("The Plan"). This resulted in an increase in the notional allocation of Ordinary Share ADRs for Mr. R Greig on September 23, 2005, at a price of $50.67 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: September 23, 2005 (Notification date: September 27, 2005).
- Individual Involved: Mr. R Greig.
- Transaction Type: Increase in notional allocation of Ordinary Share ADRs within the US Retirement Savings Plan.
- Share Price: $50.67 per share.
- Regulatory Basis: Notification required under Disclosure Rule 3.1.4R(1)(a).